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Pinocembrin flavanone inhibits cell viability in PC-3 human 
prostate cancer by inducing cellular apoptosis, ROS production 
and cell cycle arrest
The main purpose of the present study was to evaluate the 
antitumor effects of pinocembrin in human prostate cancer 
cells (PC-3) along with investigating its effects on cell apop-
tosis, endogenous ROS production and cell cycle. MTT assay 
and clonogenic assays were used to study the effects on cell 
viability and cancer colony formation, respectively. Fluores-
cence microscopy along with Western blotting was used to 
study apoptotic effects induced by pinocembrin. Flow cyto-
metry was used to study effects on ROS production and cell 
cycle phase distribution. Results indicated that pinocembrin 
promoted inhibition cell proliferation along with reducing 
cancer colony formation of PC-3 cells in a dose-dependent 
manner. Pinocembrin induced regulatory effects over 
 expressions of caspase-3, caspase-9, Bax and Bcl-2, thereby 
promoting apoptotic cell death in PC-3 cells. It also led to the 
dose-dependent G0/G1 cell cycle arrest. In conclusion, 
 pinocembrin exhibits strong anticancer effects in human 
prostate cancer cells mediated via apoptosis, endogenous 
ROS production and G0/G1 cell cycle arrest.
Keywords: prostate cancer, flavones, pinocembrin, apoptosis, 
cell cycle arrest
Pinocembrin or 5,7-dihydroxyflavanone is an active flavone molecule with remarkable 
therapeutic potential like other flavones (apigenin, kaempferol and chrysin) (1, 2). Flavones 
have been identified throughout kingdom Plantae as key secondary metabolites typically 
belonging to the benzopyran class of natural products (3, 4). Flavones disclose both lipo-
philic and hydrophilic activities including modulatory effects on several cellular enzymes. 
Other than antimicrobial activities in plants, flavones demonstrate significant biological 
and pharmacological activities against various metabolic disorders in humans (5). These 
include anticancer, antimicrobial, antioxidant, vascular, anti-allergic, anti-inflammatory, 
cytotoxic, antimalarial and antiestrogenic activities (6–8). Moreover, flavones have been 
used against different metabolic complications like atherosclerosis, Alzheimer’s disease, 
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plants including Euphorbia hirta Linn., Eriodictyon californicum and Cryptocarya chinensis, 
and purified using different techniques of chromatography (10–12). This molecule is of 
significant importance to the pharmaceutical industry due to its multifunctional behav-
iour. Pinocembrin is reported to possess antioxidant, antimicrobial, anticancer and anti-
inflammatory properties (13–16). Moreover, the pinocembrin molecule has a broad thera-
peutic time window against cerebral ischemic injury and acts as a neuroprotective agent. 
Pinocembrin inhibits the growth and proliferation of different human colon and leukae-
mia cancer cell lines. Prostate cancer is a harmful and frequently diagnosed non-cutane-
ous malignancy prevailing among men globally (17). In the year 2017, the United States of 
America had nearly 3.3 million survivors and nearly 1.7 million new diagnoses related to 
prostate cancer (18). Besides, the disease often shows slow growth and progression, it 
ranks third among cancer-related mortality in men. Maximum numbers of patients with 
prostate cancer are diagnosed at advanced stages due to its asymptotic behaviour; before 
the accessibility to PSA (prostate-specific antigen) testing. The development of prostate 
cancer has been linked to a number of risk factors including genetic mutation (BRCA-1 or 
BRCA-2), family history, older age and sub-Saharan African ancestry (19). Active investiga-
tion, radiation therapy and surgery remain key methodologies in the treatment of local-
ized prostate cancer. Androgen-deprivation therapy is used as a standard of care for new-
ly detected metastatic prostate cancer. Chemotherapy has enhanced survival chances in 
some risk groups if considered initially. Therefore, to enhance the survival rate in all risk 
groups the need for innovative therapeutic candidates arises. Keeping in consideration the 
anticancer activity of the pinocembrin molecule, the current investigation was designed to 
explore its anticancer potential against prostate cancer PC-3 cells. The effects on apoptosis, 
endogenous ROS production and cell cycle arrest were also investigated.
EXPERIMENTAL
Chemicals, reagents, cell culture and conditions
Following are the chemical reagents and drugs used in the present study. Pinocem-
brin (HPLC purity ≥ 98 %), 5-fluorouracil (5-FLU), acridine orange/ethidium bromide, 
DCFDA (2′,7′-dichlorodihydrofluorescein diacetate), Cellular ROS Assay Kit and crystal 
violet were obtained from Sigma Aldrich (USA). Culturing of the cells was performed 
within DMEM (Dulbecco’s Modified Eagle Medium), purchased from Gibco BRL (USA). 
Antibodies were purchased from Cell Signalling Technology (USA). The human prostate 
cancer PC-3 cells were American Type Culture Collection (USA). These cells were cultured 
within DMEM bearing FBS (Fetal bovine serum) (10 %), standard antibiotics (penicillin G 
of concentration 100 U mL–1 and streptomycin of concentration 100 µg mL–1) and placed 
under an environment of 5 % CO2 and 95 % air in an incubator at 37 °C.
Viability assays (proliferation and colony formation assessment)
Vybrant® MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) Cell 
Proliferation Assay Kit (ThermoFisher Scientific, USA) was used to analyse cell growth of 
PC-3 cancerous prostate cells after pinocembrin treatment. Briefly, cells were plated onto 
96-well plates at 2.5 × 105 cells in each well for 24 h. Thereafter, pinocembrin at variant 
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concentrations of 0, 6, 12, 24 and 48 µmol L–1, was supplemented to each well followed by 
incubation for 12 h and 24 h, at 37 °C. Treated cells were washed with phosphate-buffered 
saline (PBS) prior to staining with MTT solution. MTT staining was performed with 
 Vybrant® MTT Cell Proliferation Assay Kit for 4 h by strictly following the manufacturer’s 
protocol. The addition of MTT solution leads to the formation of formazan crystals which 
were then dissolved in 500 µL of dimethylsulfoxide. Finally, optical density was calcu-
lated by recording absorbance at 540 nm with an ELISA plate reader (HuaMei Inc. Wuhan, 
China). To estimate cancer colony generation by PC-3 cells, the clonogenic assay was 
performed. Exponentially growing PC-3 cells were collected and loaded to 6-well plates 
with 400 cells each well. These well plates were subjected to incubation for 48 h prior to 
treatment with variant pinocembrin doses viz. 0, 12, 24 and 48 µmol L–1. Thereafter, treated 
cells were left untouched, replacing DMEM after every 3 days, for 12 days. Afterwards, 
PC-3 cell colonies were washed with PBS followed by fixation in methyl alcohol. Finally, 
PC-3 colonies were counted under a light microscope (BD-NE610, Shenzhen Boshida 
 Instrument Co., Ltd. (China) and colonies with ≥ 50 cells were considered significant for 
counting.
Apoptosis assay
To examine the apoptosis-inducing potential of the pinocembrin drug, the acridine 
orange/ethidium bromide (AO/EB) staining assay was performed. In brief, the PC-3 cells 
were plated onto a 24-well plate at 2 × 105 cells in each well followed by pinocembrin treat-
ment at different doses of 0, 12, 24 and 48 µmol L–1 for 48 h. Thereafter, pinocembrin treated 
PC-3 cells were stained with AO/EB staining solution by obeying the manufacturer’s 
 protocol. Cancerous PC-3 cells were finally analysed under a magnification power of 200× 
of FV500 laser scanning confocal microscope (Olympus, Japan).
Flow cytometry
To monitor different cell-cycle checkpoints, flow cytometric examination of pinocem-
brin treated PC-3 cells was performed. Exponentially growing PC-3 cells were exposed to 
the pinocembrin drug with varying doses 0, 12, 24 and 48 µmol L–1 for 48 h within 6-well 
plates. Then were trypsinized using trypsin followed by staining with nuclei staining buffer 
(0.1 % Triton X-100, 3.8 mmol L–1 sodium citrate, PI (propidium iodide) solution (50 µg mL–1), 
and RNase B (7 kU mL–1) for 2 h. The cells at different cell cycle checkpoints were measured 
with the help of the Becton-Dickinson FACScan cytofluorometer (USA).
Measurements of reactive oxygen species (ROS)
The DCFH-DA staining was used to estimate ROS production in pinocembrin treated 
PC-3 cancerous prostate cells. PC-3 cells were cultured under a humidified atmosphere of 
5 % CO2 and 95 % air within a DMEM for 24 h. These cells were harvested and collected 
for pinocembrin treatment with different concentrations viz. 0, 12, 24 and 48 µmol L–1 for 
48 h. Pinocembrin-treated cells were washed using PBS and then resuspended in 500 µL 
of 10 µmol L–1 DCFH-DA for 30 min in dark. Finally, cells were analysed at an emission 
of ~520 nm and excitation of ~485 nm through FACSCanto II Flow Cytometer (BD Biosci-
ences, USA).
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Western blotting assay
The PC-3 cancerous prostate cells were harvested at 85 % of growth confluence and 
subjected to pinocembrin treatment at different doses of 0, 12, 24 and 48 µmol L–1 for 24 h. 
Treated cells were sampled into different groups and lysed using RIPA (Radioimmuno-
precipitation assay) lysis buffer. The amount of protein within each lysate was determined 
using bicinchoninic acid assay and equal amounts were loaded onto SDS-PAGE for separa-
tion followed by transferal to PVDF (polyvinylidene fluoride) membranes. These mem-
branes were blotted with specific primary antibodies (antibodies against Caspase-3 and -9, 
Bcl-2 and Bax proteins) overnight at 4 °C. Thereafter, membranes were treated with HRP-
conjugated secondary antibodies. Finally, visualization of immunoreactive bands was pre-
pared by using the ImageQuant LAS4000 system (GE Healthcare, USA).
Statistical analysis
All the data collected from individual experiments were analysed by using GraphPad 
Prism Demo (version 5; USA) and are expressed as mean ± SD. The p < 0.05 and p < 0.01 
were taken as statistically significant. Each experiment for individual drug doses was per-
formed in triplicate.
RESULTS AND DISCUSSION
Pinocembrin induced antiproliferative effects in PC-3 cells
Despite cancer treatment going through significant advancements, treatment of pros-
tate cancer remains a big challenge for researchers. The disease remains poorly diagnosed 
at early stages due to asymptotic behaviour (20). Pinocembrin has been previously re-
ported to suppress the proliferation rate in a number of human cancer cells. In a similar 
study, pinocembrin attenuated the cell viability of androgen-sensitive LNCaP and andro-
gen-independent PC3 and DU-145 prostate cancer cell lines (21).
Herein, PC-3 cancerous prostate cells were analysed for viability assessment through 
MTT assay by following the manufacturer protocol. The proliferation rate was signifi-
cantly retarded after exposing PC-3 cells to different pinocembrin (Fig. 1) doses (0–48 µmol 
L–1). Pinocembrin induced toxicity enhanced after elongating treatment time from 12 to 24 
h. Viability was reduced to almost 40 and 20 % at 48 µmol L–1 after 12 and 24 h of pinocem-
brin treatment, respectively (Fig. 2a). Pinocembrin showed almost comparable antiprolif-
erative effects against positive controls with 5-fluorouracil (5-FLU) treated cells). More-
over, the antiproliferative effect of pinocembrin against normal non-cancerous cells, 
Fig. 1. Chemical structure of pinocembrin.
673
L. Shao et al.: Pinocembrin flavanone inhibits cell viability in PC-3 human prostate cancer by inducing cellular apoptosis, ROS 
 production and cell cycle arrest, Acta Pharm. 71 (2021) 669–678.
 
human dermal microvascular endothelial cells (HDMECs) was much lower than PC-3 cells 
(Fig. 2b). The ability of prostate PC-3 cancer cells to generate and establish colonies was 
monitored by performing the clonogenic assay. Pinocembrin revealed remarkable toxicity 
against PC-3 cell colonies (Fig. 3a). Pinocembrin reduced PC-3 colonies to about 100 at 48 
µmol L–1 in comparison to controls which showed about 400 intact colonies after 12 days 
of culturing (Fig. 3b). Therefore, the results from MTT assay and colony assessment indi-
cated that pinocembrin induced remarkable cytotoxicity against PC-3 cell proliferation 
and colony generation.
Pinocembrin caused apoptotic cell death in PC-3 cells
Apoptosis (natural programmed cell death) is a highly conserved process in mammals 
and plays a key role in the elimination of damaged, malfunctioning and aged cells. Prevention 
Fig. 2. a) Estimation of the PC-3 cancerous prostate cells viability after pinocembrin treatment at indi-
cated concentration and time intervals. The figure represents the declined number of viable cells after 
exposure to pinocembrin in comparison to the control group. 5-Fluorouracil (5-FLU) was used as a 
positive control; b) Effect of pinocembrin on non-cancerous normal cells (human dermal microvascular 
endothelial cells, HDMECs). Cytotoxicity of pinocembrin was evaluated against these after treatment 
with the drug for 24 h. The cell viability of these HDMECs after incubation with pinocembrin for 24 h 
was much higher than that of similarly treated PC-3 cancer cells. Each experiment was repeated three 
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of apoptosis in normal cells transfers them to tumorous cells which then undergo uncon-
trolled hyper-proliferation (22). Therefore, apoptosis plays a key role in inhibiting the prolife-
ration of cancer cells and serves as a potential target for chemopreventives. Pinocembrin has 
been shown to promote apoptosis in different human cancers. A study carried out by Zheng 
et al. has reported that pinocembrin promotes apoptosis via modulation of Bcl-2/Bax ratio 
and suppresses autophagy in human melanoma cells including A375 and B16F10 (23). In a 
similar study, pinocembrin has been shown to produce protective effects via the mito-
chondrial apoptotic pathway in SH-SY5Y neuroblastoma cells against MPP+-induced neuro-
toxicity (24). Similarly, pinocembrin has been previously reported to induce apoptotic cell 
death in HT-29 and HCT-116 colon cancer and HL-60 leukaemia cells (25).
Herein, AO/EB staining showed that the normal morphology of PC-3 cells was dis-
turbed after the application of pinocembrin at variant doses. Pinocembrin enhanced the 
number of apoptotic PC-3 cells with increasing doses. The yellow-green, orange-red and red 
fluorescent cells indicate the number of early and late apoptotic and necrotic cells respecti-
vely (Fig. 4a). Thus AO/EB staining indicated stimulation of apoptotic cell death in PC-3 cells 
post pinocembrin treatment. Moreover, apoptosis stimulation by pinocembrin was  supported 
by Western blotting at molecular levels. The activity of Caspase-9, Caspase-3and Bax  proteins 
increased and that of Bcl-2 protein decreased with increasing pinocembrin doses (Fig. 4b). 
Hence, AO/EB staining supported by Western blotting indicated that the antiproliferative 
effects of pinocembrin could be due to its apoptosis stimulation effects in PC-3 cells.
Fig. 3. a) Clonogenic assessment of pinocembrin treated PC-3 cells at variant concentrations; b) Results 
representing inhibitory effects of pinocembrin at indicated concentrations on PC-3 cells. Each 
 experiment was repeated three times and data are presented as mean ± SD. The statistical significant 




L. Shao et al.: Pinocembrin flavanone inhibits cell viability in PC-3 human prostate cancer by inducing cellular apoptosis, ROS 
 production and cell cycle arrest, Acta Pharm. 71 (2021) 669–678.
 
Pinocembrin inhibited cell cycle progression in PC-3 cells
The tendency of hyper-proliferation of cancer cells leads to fast growth and spread of 
the disease. Therefore, controlling and checking of proliferation rate remains a principal 
objective of chemopreventives. Pinocembrin has been previously reported to cause G2/M- 
Fig. 4. a) The AO/EB staining assay was implemented for the determination of apoptosis stimulatory 
potential of the pinocembrin drug in PC-3 cells. The figure shows yellow-green, orange-red and red 
fluorescence that indicates early, late apoptotic and necrotic cells, respectively; b) Western blotting 
assay. The figure depicts enhanced expressions of caspases and Bax proapoptotic proteins and 
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and S-Phase cell cycle arrest in prostate LNCaP cancer cells (21). Herein, flow cytometric 
measurements were carried out for the estimation of PC-3 cells at different cell cycle check-
points. Results indicated that the number of cells at S and G2/M phases declined with 
Fig. 5. Analysis of cell cycle phase distribution by flow cytometry after 48 h of pinocembrin treatment 
of cancerous PC-3 cells. Pinocembrin triggered cell cycle arrest of cancerous PC-3 cells at the G0/G1 
checkpoint in a concentration-dependent manner. Each experiment was repeated three times and 
data are presented as mean ± SD. The statistical significant figure was taken as p < 0.05. 
Fig. 6. a) Effects of pinocembrin drug on cancerous PC-3 cells after 48 h long treatment and then stain-
ing with DCFH-DA. Fluorescence intensity of DCFH-DA is directly proportional to ROS production in 
pinocembrin treated PC-3 cells. Each experiment was repeated three times; b) Graphical representation 
of the effect of pinocembrin on the ROS production in PC-3 cells, as can be seen, there was a dose- 
- dependent increase in the percentage of cells with damaged cell membranes indicating significant 
ROS production leading to collapse of mitochondrial membrane potential. Each experiment was 
 repeated three times and data are presented as mean ± SD. Statistical significance was taken as * p < 0.05.
a)                                                                               b)
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enhanced doses of pinocembrin while the number of cells at G0/G1 cells amplified. The 
number of G0/G1 cells enhanced to almost 60 % in comparison to about 25 % in the control 
group (Fig. 5).
Pinocembrin enhanced ROS in PC-3 cells
ROS are considered lethal entities that disturb a large number of normal cellular pro-
cesses. As these species are highly reactive they can target any cellular mechanism. Herein, 
the effects of pinocembrin upon ROS in PC-3 cells were assessed by DCFH-DA staining 
assay. The results indicated enhanced DCFH-DA fluorescence (directly proportional to 
ROS) with increasing pinocembrin treatment (Fig. 6a). Therefore, it may be concluded that 
the antiproliferative effects of pinocembrin are also allied with enhanced ROS. Fig. 6b 
shows the graphical increase in ROS production with an increase in pinocembrin dose.
CONCLUSIONS
Taken altogether, the results of the current investigation indicate that pinocembrin 
flavanone exhibited significant antitumor effects against prostate tumor PC-3 cells. These 
effects were mediated through stimulation of apoptosis, endogenous ROS production and 
cell cycle arrest.
REFERENCES
 1.  G. Zhao, G. W. Qin, J. Wang, W. J. Chu and L. H. Guo, Functional activation of monoamine trans-
porters by luteolin and apigenin isolated from the fruit of Perilla frutescens (L.), Neurochem. Int. 56 
(2010) 168–176; https://doi.org/10.1016/j.neuint.2009.09.015
 2.  J. A. Van Meeuwen, N. Korthagen, P. C. De Jong, A. H. Piersma and M. Van den Berg, (Anti) estro-
genic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their 
co-culture, Toxicol. Appl. Pharmacol. 221 (2007) 372–383; https://doi.org/10.1016/j.taap.2007.03.016
 3.  X. Su, L. Kong, X. Lei, L. Hu, M. Ye and H. Zou, Biological fingerprinting analysis of traditional 
Chinese medicines with targeting ADME/Tox property for screening of bioactive compounds by 
chromatographic and MS methods, Mini Rev. Med. Chem. 7 (2007) 87–98; https://doi.
org/10.2174/138955707779317830
 4.  T. Y. K. Chan, J. C. N. Chan, B. Tomlinson and J. A. J. H. Critchley, Chinese herbal medicines re-
visited: a Hong Kong perspective, Lancet 342 (1993) 1532–1534; https://doi.org/10.1016/S0140-
6736(05)80091-1
 5.  A. K. Verma and R. Pratap, The biological potential of flavones, Nat. Prod. Rep. 27 (2010) 1571–1593.
 6.  T. Guardia, A. O. Juarez and L. E. Pelzer, Anti-inflammatory properties of plant flavonoids. Effects 
of rutin, quercetin and hesperidin on adjuvant arthritis in rat, Il Farmaco 56 (2001) 683–687; https://
doi.org/10.1016/S0014-827X(01)01111-9
 7.  C. H. Jung, C. H. Cho and C. J. Kim, Anti-asthmatic action of quercetin and rutin in conscious 
guinea-pigs challenged with aerosolized ovalbumin, Arch. Pharm. Res. 30 (2007) 1599–1607; https://
doi.org/10.1007/BF02977330
 8.  G. B. Reddy, P. Muthenna, C. Akileshwari, V. Saraswat and J. M. Petrash, Inhibition of aldose 
 reductase and sorbitol accumulation by dietary rutin, Curr. Sci. 101 (2011) 1191–1197.
 9.  J. B. Harborne and C. A. Williams, advances in flavonoid research since 1992, Phytochemistry 6 
(2000) 481–504; https://doi.org/10.1016/S0031-9422(00)00235-1
678
L. Shao et al.: Pinocembrin flavanone inhibits cell viability in PC-3 human prostate cancer by inducing cellular apoptosis, ROS 
 production and cell cycle arrest, Acta Pharm. 71 (2021) 669–678.
 
10.  Y. Wu, W. Qu, D. Geng, J. Y. Liang and Y. L. Luo, Phenols and flavonoids from the aerial part of 
Euphorbia hirta, Chin. J. Nat. Med. 10 (2012) 40–42; http://dx.doi.org/10.3724/SP.J.1009.2012.00040
11.  T. H. Chou, J. J. Chen, C. F. Peng, M. J. Cheng and I. S. Chen, New flavanones from the leaves of 
Cryptocarya chinensis and their antituberculosis activity, Chem. Biodivers. 8 (2011) 2015–2024; https://
doi.org/10.1002/cbdv.201000367
12.  Y. L. Liu, D. K. Ho, J. M. Cassady, V. M. Cook and W. M. Baird, Isolation of potential cancer 
 chemopreventive agents from Eriodictyon californicum, J. Nat. Prod. 55 (1992) 357–363; https://doi.
org/10.1021/np50081a012
13.  X. Lan, W. Wang, Q. Li and J. Wang, The natural flavonoid pinocembrin: molecular targets and 
potential therapeutic applications, Mol. Neurobiol. 53 (2016) 1794–1801; https://dx.doi.
org/10.1007%2Fs12035-015-9125-2
14.  M. A. S. Kumar, M. Nair, P. S. Hema, J. Mohan and T. R. Santhoshkumar, Pinocembrin triggers 
Bax-dependent mitochondrial apoptosis in colon cancer cells, Mol. Carcinog. 46 (2007) 231–241, 
https://doi.org/10.1002/mc.20272
15.  L. Estevinho, A. P. Pereira, L.Moreira, L. G. Dias and E. Pereira, Antioxidant and antimicrobial 
effects of phenolic compounds extracts of Northeast Portugal honey, Food Chem. Toxicol. 46 (2008) 
3774–3779; https://doi.org/10.1016/j.fct.2008.09.062
16.  R. Feng, Z. K. Guo, C. M. Yan, E. G. Li, R. X. Tan and H. M. Ge, Anti-inflammatory flavonoids from 
Cryptocarya chingii, Phytochemistry 76 (2012) 98–105; https://doi.org/10.1016/j.phyto-
chem.2012.01.007
17.  R. L. Siegel and A. Miller Jemal, Cancer statistics, 2017, CA Cancer J. Clin. 67 (2017) 7–30; https://doi.
org/10.3322/caac.21442
18.  Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Statistics (2007–2013), Pros-
tate Cancer, Bethesda, MD: National Cancer Institute, USA.
19.  S. E. Eggener, A. S. Cifu and C. Nabhan, Prostate cancer screening, JAMA. 314 (2015) 825–826.
20.  R. Etzioni, R. Cha, E. J. Feuer and O. Davidov, Asymptomatic incidence and duration of prostate 
cancer, Am. J. Epidemiol. 148 (1998) 775–785; https://doi.org/10.1097/00005392-199907000-00083
21.  Z. Chen, A. Rasul, C. Zhao, F. M. Millimouno, I. Tsuji, T. Yamamura, R. Iqbal, M. Malhi, X. Li and 
J. Li, Antiproliferative and apoptotic effects of pinocembrin in human prostate cancer cells, 
 Bangladesh J. Pharmacol. 8 (2013) 255–262; https://doi.org/10.3329/bjp.v8i3.14795
22.  A. Rahman, S. Pallichankandy, F. Thayyullathil and S. Galadari, Critical role of H2O2 in mediating 
sanguinarine-induced apoptosis in prostate cancer cells via facilitating ceramide generation, 
ERK1/2 phosphorylation, and Par-4 cleavage, Free Radic. Biol. Med. 134 (2019) 527–544; https://doi.
org/10.1016/j.freeradbiomed.2019.01.039
23.  Y. Zheng, K. Wang, Y. Wu, Y. Chen, X. Chen, C. W. Hu and F. Hu, Pinocembrin induces ER stress 
mediated apoptosis and suppresses autophagy in melanoma cells, Cancer Lett. 431 (2018) 31–42; 
https://doi.org/10.1016/j.canlet.2018.05.026
24.  M. Gao, W. C. Zhang, Q. S. Liu, J. J. Hu, G. T. Liu and G. H. Du, Pinocembrin prevents glutamate-
induced apoptosis in SH-SY5Y neuronal cells via decrease of bax/bcl-2 ratio, Eur. J. Pharmacol. 591 
(2008) 73–79; https://doi.org/10.1016/j.ejphar.2008.06.071
25.  A. Rasul, F. M. Millimouno, W. Ali Eltayb, M. Ali, J. Li and X. Li, Pinocembrin: a novel natural 
compound with versatile pharmacological and biological activities, Biomed Res. Int. 2013 (2013) 
1–9; https://doi.org/10.1155/2013/379850
